Sphincter-saving surgery after neoadjuvant therapy for ultra-low rectal cancer where abdominoperineal resection was indicated: 10-year results of the GRECCAR 1 trial - Centre Oscar Lambret Accéder directement au contenu
Article Dans Une Revue British Journal of Surgery Année : 2021

Sphincter-saving surgery after neoadjuvant therapy for ultra-low rectal cancer where abdominoperineal resection was indicated: 10-year results of the GRECCAR 1 trial

Résumé

This phase III trial included patients with ultra-low rectal adenocarcinoma that initially required abdominoperineal resection. The surgical decision was based on clinical tumour status after preoperative treatment. The overall sphincter-saving resection rate was 85 per cent, with 72 per cent rate of intersphincteric resection. Long-term results showed that changing the initial abdominoperineal resection indication into a sphincter-saving resection according to tumoral response is oncologically safe. Saving the sphincter
Fichier non déposé

Dates et versions

hal-03657636 , version 1 (03-05-2022)

Identifiants

Citer

P Rouanet, M Rivoire, S Gourgou, B Lelong, E Rullier, et al.. Sphincter-saving surgery after neoadjuvant therapy for ultra-low rectal cancer where abdominoperineal resection was indicated: 10-year results of the GRECCAR 1 trial. British Journal of Surgery, 2021, 108 (1), pp.10-13. ⟨10.1093/bjs/znaa010⟩. ⟨hal-03657636⟩
9 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More